Clinical Trial Update: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating serial circulating tumor DNA monitoring during adjuvant capecitabine in early triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Stanford University | Conditions: Triple Negative Breast Cancer, Breast Cancer | Phase 2 | Status: RECRUITING